Setting

North America Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity

Published: 26 Aug 2020 | Report Code: 10247662 | Pages: 139

North America digital biomarkers market is expected to grow by 35.8% annually in the forecast period and reach $6,747.2 million by 2030 driven by rising demand for mobile health apps, elevated level of smartphone and wearable technology in healthcare amid COVID-19 epidemic. Highlighted with 32 tables and 63 figures, this 139-page report “North America Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America digital biomarkers market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America digital biomarkers market in every aspect of the classification from perspectives of System Component, Therapeutic Area, Application, Development Status, End User, and Country. Based on System Component, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Data Collection Tools • Digital Platforms • Mobile Apps • Desktop-based Software • Wearables • Biosensors Data Integration Systems Based on Therapeutic Area, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Cardiovascular Diseases Neurodegenerative Disorders • Parkinson’s Disease • Multiple Sclerosis • Alzheimer’s Disease Sleep and Movement Diseases Psychiatric Disorders Chronic Pain Gastrointestinal Diseases Diabetes Respiratory Conditions Other Diseases Based on Application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Wellness • Disease Diagnosis • Personalised Medication • Drug Discovery and Development Based on Development Status, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Novel Digital Biomarkers • Original Digital Biomarkers • Approved Digital Biomarkers Based on End User, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Biopharmaceutical Companies & Labs • Healthcare Providers • Insurance Payers Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by System Component, Therapeutic Area, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in North America digital biomarkers market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Actigraph LLC Akili Interactive Labs AliveCor Inc Altoida Inc Amgen Inc Bayer AG Biogen Inc Cambridge Cognition Plc Eli Lilly and Company Evidation Health, Inc. F. Hoffmann-La Roche Ltd Fitbit Inc GlaxoSmithKline Plc Happify Health Human API IXICO Plc Koninklijke Philips N.V. Medical Care Corporation Medopad Ltd Mindstrong Health Neurotrack Technology, Inc Novartis International AG Pfizer Inc. Quanterix Corporation Sanofi S.A. The Takeda Pharmaceuticals Company Limited Verily Life Sciences Winterlight Labs Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction 7 1.1 Industry Definition and Research Scope 7 1.1.1 Industry Definition 7 1.1.2 Research Scope 8 1.2 Research Methodology 11 1.2.1 Overview of Market Research Methodology 11 1.2.2 Market Assumption 12 1.2.3 Secondary Data 12 1.2.4 Primary Data 12 1.2.5 Data Filtration and Model Design 14 1.2.6 Market Size/Share Estimation 15 1.2.7 Research Limitations 16 1.3 Executive Summary 17 2 Market Overview and Dynamics 20 2.1 Market Size and Forecast 20 2.1.1 Impact of COVID-19 on the Market 25 2.2 Major Growth Drivers 27 2.3 Market Restraints and Challenges 32 2.4 Emerging Opportunities and Market Trends 37 2.5 Porter’s Fiver Forces Analysis 41 3 Segmentation of North America Market by System Component 45 3.1 Market Overview by System Component 45 3.2 Data Collection Tools 47 3.2.1 Digital Platforms 49 3.2.2 Mobile Apps 50 3.2.3 Desktop-based Software 51 3.2.4 Wearables 52 3.2.5 Biosensors 53 3.3 Data Integration Systems 54 4 Segmentation of North America Market by Therapeutic Area 55 4.1 Market Overview by Therapeutic Area 55 4.2 Cardiovascular Diseases 57 4.3 Neurodegenerative Disorders 58 4.3.1 Parkinson’s Disease 60 4.3.2 Multiple Sclerosis 61 4.3.3 Alzheimer’s Disease 62 4.4 Sleep and Movement Diseases 63 4.5 Psychiatric Disorders 64 4.6 Chronic Pain 65 4.7 Gastrointestinal Diseases 66 4.8 Diabetes 67 4.9 Respiratory Conditions 68 4.10 Other Diseases 69 5 Segmentation of North America Market by Application 70 5.1 Market Overview by Application 70 5.2 Wellness 72 5.3 Disease Diagnosis 73 5.4 Personalised Medication 74 5.5 Drug Discovery and Development 75 6 Segmentation of North America Market by Development Status 77 6.1 Market Overview by Development Status 77 6.2 Novel Digital Biomarkers 80 6.3 Original Digital Biomarkers 81 6.4 Approved Digital Biomarkers 82 7 Segmentation of North America Market by End User 83 7.1 Market Overview by End User 83 7.2 Biopharmaceutical Companies & Labs 85 7.3 Healthcare Providers 86 7.4 Insurance Payers 87 8 North America Market 2019-2030 by Country 88 8.1 Overview of North America Market 88 8.2 U.S. 91 8.3 Canada 95 8.4 Mexico 97 9 Competitive Landscape 99 9.1 Overview of Key Vendors 99 9.2 New Product Launch, Partnership, Investment, and M&A 103 9.3 Company Profiles 104 Actigraph LLC 104 Akili Interactive Labs 106 AliveCor Inc 107 Altoida Inc 108 Amgen Inc 109 Bayer AG 110 Biogen Inc 111 Cambridge Cognition Plc 112 Eli Lilly and Company 113 Evidation Health, Inc. 114 F. Hoffmann-La Roche Ltd 115 Fitbit Inc 116 GlaxoSmithKline Plc 117 Happify Health 118 Human API 119 IXICO Plc 120 Koninklijke Philips N.V. 121 Medical Care Corporation 122 Medopad Ltd 123 Mindstrong Health 124 Neurotrack Technology, Inc 125 Novartis International AG 126 Pfizer Inc. 127 Quanterix Corporation 128 Sanofi S.A. 129 The Takeda Pharmaceuticals Company Limited 130 Verily Life Sciences 131 Winterlight Labs Inc. 132 10 Investing in North America Market: Risk Assessment and Management 133 10.1 Risk Evaluation of North America Market 133 10.2 Critical Success Factors (CSFs) 136 Related Reports and Products 139
List Of Tables

Table 1. Snapshot of North America Digital Biomarkers Market, 2019-2030 18 Table 2. Overview of Traditional and Digital Biomarker Features, Novel Applications, and Published Examples 22 Table 3. World Smartphone Connections, Average Network Connection Speed for Smartphones and Tablets, 2019-2030 30 Table 4. World Mobile Data Traffic by Deployment Mode, 2019-2030, EB/year 31 Table 5. World Mobile Data Traffic by Device, 2019-2030, EB/year 31 Table 6. Current Challenges of Digital Biomarkers in Medical Settings 34 Table 7. Main Product Trends and Market Opportunities in North America Digital Biomarkers Market 37 Table 8. North America Digital Biomarkers Market by System Component, 2019-2030, $ mn 45 Table 9. North America Digital Biomarkers Market: Data Collection Tools by Type, 2019-2030, $ mn 48 Table 10. North America Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 55 Table 11. North America Digital Biomarkers Market: Neurodegenerative Disorders by Type, 2019-2030, $ mn 59 Table 12. North America Digital Biomarkers Market by Application, 2019-2030, $ mn 70 Table 13. North America Digital Biomarkers Market by Development Status, 2019-2030, $ mn 78 Table 14. North America Digital Biomarkers Market by End User, 2019-2030, $ mn 83 Table 15. North America Digital Biomarkers Market by Country, 2019-2030, $ mn 89 Table 16. U.S. Digital Biomarkers Market by System Component, 2019-2030, $ mn 93 Table 17. U.S. Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 93 Table 18. U.S. Digital Biomarkers Market by End User, 2019-2030, $ mn 93 Table 19. Canada Digital Biomarkers Market by System Component, 2019-2030, $ mn 96 Table 20. Canada Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 96 Table 21. Canada Digital Biomarkers Market by End User, 2019-2030, $ mn 96 Table 22. Mexico Digital Biomarkers Market by System Component, 2019-2030, $ mn 98 Table 23. Mexico Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 98 Table 24. Mexico Digital Biomarkers Market by End User, 2019-2030, $ mn 98 Table 25. Breakdown of North America Market by Key Vendor, 2019, % 101 Table 26. Actigraph LLC: Company Snapshot 104 Table 27. Actigraph LLC: Business Segmentation 104 Table 28. Actigraph LLC: Product Portfolio 105 Table 29. Actigraph LLC: Revenue, 2016-2018, $ mn 105 Table 30. Actigraph LLC: Recent Developments 105 Table 31. Risk Evaluation for Investing in North America Market, 2019-2030 134 Table 32. Critical Success Factors and Key Takeaways 137
List Of Figures

Figure 1. Research Method Flow Chart 11 Figure 2. Breakdown of Primary Research 13 Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15 Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17 Figure 5. North America Digital Biomarkers Market, 2019-2030, $ mn 20 Figure 6. Category and Relationship of Traditional Biomarkers and Digital Biomarkers 21 Figure 7. Benefits and Challenges of Digital Biomarkers 23 Figure 8. North America Biomarkers Market, 2019-2030, $ mn 24 Figure 9. Share of Digital Biomarkers in Total Biomarkers Market, 2019-2030 24 Figure 10. Impact of COVID-19 on Business 25 Figure 11. Primary Drivers and Impact Factors of North America Digital Biomarkers Market 27 Figure 12. World 5G Traffic, 2019-2030, EB/year 30 Figure 13. Primary Restraints and Impact Factors of North America Digital Biomarkers Market 32 Figure 14. Data Security Risk in Various User Groups of Digital Biomarkers 35 Figure 15. Pathway to Regulatory Approval of Digital Biomarkers 36 Figure 16. Investment Opportunity Analysis 38 Figure 17. Porter’s Fiver Forces Analysis of North America Digital Biomarkers Market 41 Figure 18. Breakdown of North America Digital Biomarkers Market by System Component, 2019-2030, % of Revenue 46 Figure 19. North America Addressable Market Cap in 2020-2030 by System Component, Value ($ mn) and Share (%) 46 Figure 20. North America Digital Biomarkers Market: Data Collection Tools, 2019-2030, $ mn 47 Figure 21. North America Digital Biomarkers Market: Digital Platforms, 2019-2030, $ mn 49 Figure 22. North America Digital Biomarkers Market: Mobile Apps, 2019-2030, $ mn 50 Figure 23. North America Digital Biomarkers Market: Desktop-based Software, 2019-2030, $ mn 51 Figure 24. North America Digital Biomarkers Market: Wearables, 2019-2030, $ mn 52 Figure 25. North America Digital Biomarkers Market: Biosensors, 2019-2030, $ mn 53 Figure 26. North America Digital Biomarkers Market: Data Integration Systems, 2019-2030, $ mn 54 Figure 27. Breakdown of North America Digital Biomarkers Market by Therapeutic Area, 2019-2030, % of Sales Revenue 56 Figure 28. North America Addressable Market Cap in 2020-2030 by Therapeutic Area, Value ($ mn) and Share (%) 56 Figure 29. North America Digital Biomarkers Market: Cardiovascular Diseases, 2019-2030, $ mn 57 Figure 30. North America Digital Biomarkers Market: Neurodegenerative Disorders, 2019-2030, $ mn 58 Figure 31. North America Digital Biomarkers Market: Parkinson’s Disease, 2019-2030, $ mn 60 Figure 32. North America Digital Biomarkers Market: Multiple Sclerosis, 2019-2030, $ mn 61 Figure 33. North America Digital Biomarkers Market: Alzheimer’s Disease, 2019-2030, $ mn 62 Figure 34. North America Digital Biomarkers Market: Sleep and Movement Diseases, 2019-2030, $ mn 63 Figure 35. North America Digital Biomarkers Market: Psychiatric Disorders, 2019-2030, $ mn 64 Figure 36. North America Digital Biomarkers Market: Chronic Pain, 2019-2030, $ mn 65 Figure 37. North America Digital Biomarkers Market: Gastrointestinal Diseases, 2019-2030, $ mn 66 Figure 38. North America Digital Biomarkers Market: Diabetes, 2019-2030, $ mn 67 Figure 39. North America Digital Biomarkers Market: Respiratory Conditions, 2019-2030, $ mn 68 Figure 40. North America Digital Biomarkers Market: Other Diseases, 2019-2030, $ mn 69 Figure 41. Breakdown of North America Digital Biomarkers Market by Application, 2019-2030, % of Sales Revenue 71 Figure 42. North America Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%) 71 Figure 43. North America Digital Biomarkers Market: Wellness, 2019-2030, $ mn 72 Figure 44. North America Digital Biomarkers Market: Disease Diagnosis, 2019-2030, $ mn 73 Figure 45. North America Digital Biomarkers Market: Personalised Medication, 2019-2030, $ mn 74 Figure 46. North America Digital Biomarkers Market: Drug Discovery and Development, 2019-2030, $ mn 75 Figure 47. Classification of Digital Biomarkers by Development Status 77 Figure 48. Breakdown of North America Digital Biomarkers Market by Development Status, 2019-2030, % of Revenue 79 Figure 49. North America Addressable Market Cap in 2020-2030 by Development Status, Value ($ mn) and Share (%) 79 Figure 50. North America Digital Biomarkers Market: Novel Digital Biomarkers, 2019-2030, $ mn 80 Figure 51. North America Digital Biomarkers Market: Original Digital Biomarkers, 2019-2030, $ mn 81 Figure 52. North America Digital Biomarkers Market: Approved Digital Biomarkers, 2019-2030, $ mn 82 Figure 53. Breakdown of North America Digital Biomarkers Market by End User, 2019-2030, % of Revenue 84 Figure 54. North America Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%) 84 Figure 55. North America Digital Biomarkers Market: Biopharmaceutical Companies & Labs, 2019-2030, $ mn 85 Figure 56. North America Digital Biomarkers Market: Healthcare Providers, 2019-2030, $ mn 86 Figure 57. North America Digital Biomarkers Market: Insurance Payers, 2019-2030, $ mn 87 Figure 58. Breakdown of North America Digital Biomarkers Market by Country, 2019 and 2030, % of Revenue 89 Figure 59. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 90 Figure 60. U.S. Digital Biomarkers Market, 2019-2030, $ mn 92 Figure 61. Canada Digital Biomarkers Market, 2019-2030, $ mn 95 Figure 62. Digital Biomarkers Market in Mexico, 2015-2030, $ mn 97 Figure 63. Growth Stage of North America Digital Biomarkers Industry over the Forecast Period 99
Key Players (this may not be a complete list and extra companies can be added upon request): 
Actigraph LLC	
Akili Interactive Labs	
AliveCor Inc	
Altoida Inc	
Amgen Inc	
Bayer AG	
Biogen Inc	
Cambridge Cognition Plc	
Eli Lilly and Company	
Evidation Health, Inc.	
F. Hoffmann-La Roche Ltd	
Fitbit Inc	
GlaxoSmithKline Plc	
Happify Health	
Human API	
IXICO Plc	
Koninklijke Philips N.V.	
Medical Care Corporation	
Medopad Ltd	
Mindstrong Health	
Neurotrack Technology, Inc	
Novartis International AG	
Pfizer Inc.	
Quanterix Corporation	
Sanofi S.A.	
The Takeda Pharmaceuticals Company Limited	
Verily Life Sciences	
Winterlight Labs Inc.